Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Healius Limited ( (AU:HLS) ).
Healius Limited announced that Michael Stanford has ceased to be a director as of September 30, 2025. The announcement details his holdings, which include 40,000 ordinary shares directly and an indirect interest in 32,468 ordinary shares held by Mrs. Sally Stanford. This change in directorship may impact the company’s governance and strategic direction.
The most recent analyst rating on (AU:HLS) stock is a Hold with a A$0.87 price target. To see the full list of analyst forecasts on Healius Limited stock, see the AU:HLS Stock Forecast page.
More about Healius Limited
Healius Limited operates in the healthcare industry, providing a range of medical services and products. The company focuses on delivering healthcare solutions and services to improve patient outcomes and support the healthcare sector.
Average Trading Volume: 4,870,305
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$541M
Find detailed analytics on HLS stock on TipRanks’ Stock Analysis page.